Verona Pharma — Merger or Acquisition (July 2025)
15 slides from Verona Pharma's merger presentation, Jul 10, 2025
Slide 1: Verona Pharma Employee Town Hall with Merck
Verona Pharma Employee Town Hall with Merck Thursday, July 10, 2025
Slide 2: Forward-looking statement of Merck & Co., Inc.
Forward - looking statement of Merck & Co., Inc. This presentation of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward - looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are base
Slide 3: Additional information and where to find it
Additional information and where to find i t In connection with the proposed transaction between Verona Pharma and Merck, Verona Pharma will file with the Securities and Exchange Commission (“SEC”) a proxy statement on Schedule 14A. Additionally, Verona Pharma may file other relevant materials with
Slide 4: Participants in the solicitation
Participants in the solicitation Verona Pharma, Merck and certain of their directors and executive officers may be deemed to be participants in the solicitati on of proxies from the shareholders of Verona Pharma in connection with the proposed transaction. Information about Verona Pharma’s directors
Slide 5: Today's agenda
Today’s agenda 5 Welcome Overview of Merck Building on your scientific success Coming together for patients Next steps
Slide 6: Welcome
6 6 Welcome David Zaccardelli, President and CEO Verona Pharma
Slide 7: Overview of Merck
7 7 Overview of Merck Rob Davis, Chairman and CEO
Slide 8: We are unified around Our Purpose
We are unified around Our Purpose We use the power of leading - edge science to save and improve lives around the world “W e try never to forget that medicine is for the people. It is not for the profits. The profits follow, and if we have remembered that, they have never failed to appear. " – Georg
Slide 9: Building on your scientific success
9 9 Building on your scientific success Dean Li, President, Merck Research Laboratories
Slide 10: Together, we will address significant unmet need in COPD
Together, we will address significant unmet need in COPD 10 Clinical studies provide strong clinical validation for Ohtuvayre as a highly effective treatment for patients with moderate to severe symptomatic COPD Committed to finding the best external science to complement our internal innovation and
Slide 11: Coming together for patients
11 11 Coming together for patients Jannie Oosthuizen, President, Human Health U.S.
Slide 12: Significant opportunity to benefit patients with COPD
18 Significant opportunity to benefit patients with COPD 1,2 1. Chen, et al., Int J Chron Obstruct Pulmon Dis. 2018;13:1365 - 1376 2. Phreesia COPD Patient Perceptions Survey 3. Verona Pharma estimates ~8.6M Maintenance Treated COPD Patients 3 ~50% Persistently Symptomatic COPD Patients Regardless o
Slide 13: Next steps
13 13 Next steps Rob Davis, Chairman and CEO
Slide 14: How we'll work together
How we’ll work together 14 We are looking forward to working with you We look forward to welcoming the talented Verona Pharma team to Merck. Each of you are critical to maintaining commercial and pipeline momentum. We’ll continue to share along the way We commit to providing updates and information
Slide 15: Thank you!
Thank you!